Check Point Software Technologies Ltd vs Neurocrine Biosciences Inc — how do they compare? Check Point Software Technologies Ltd trades at $129.01 (market cap $13.18B), while Neurocrine Biosciences Inc trades at $151.32 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | NBIX | |
|---|---|---|
Market Cap | $13.18B | $16.46B |
Sector | Technology | Health |
52-Week High | $206.91 | $185.50 |
52-Week Low | $112.47 | $123.10 |
Enterprise Value | $12.88B | $16.48B |
Trailing returns across standard periods
Latest headlines on both assets
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →